Int J Clin Pharm Th
-
Int J Clin Pharm Th · May 2014
Randomized Controlled TrialEffect of dual bronchodilation with QVA149 on cardiac safety in healthy volunteers.
QVA149 is a dual bronchodilator, containing a fixed-dose combination of the long-acting β2-agonist indacaterol and long-acting muscarinic antagonist glycopyrronium, for the treatment of chronic obstructive pulmonary disease (COPD). Here we assess the potential of QVA149 (440/200 μg) at 4-fold the therapeutic dose for causing cardiac pharmacodynamic (PD) effects. ⋯ Overall, short-term administration of QVA149 showed a good cardiovascular safety and tolerability profile in healthy subjects.